Nasdaq · CIK 0001396814
PCRX Pacira BioSciences, Inc.
Insider trading from SEC Form 4. Last filing 30 h ago. Close $36.31 on Oct 9, 2026, +90% from the 52-week low and -0% from the high.
Last 90 days
Net insider value
-$218k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$218k by 1 insider
Insiders on file
3
with a Form 4 at this company
Price and insider trades, last year
Signals
Open-market buys and sells at Pacira BioSciences, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 0Weak | sell10b5-1 | RIKER LAUREN Senior Vice President, Finance | $218k | 6,000 | -9% | - | |
| 0Weak | sell10b5-1 | GAUGLER DARYL Chief Operating Officer | $9,880 | 500 | -0% | - |
Transactions
The last 6 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | RIKER LAUREN Senior Vice President, Finance | MOption exercise Common Stock10b5-1 | +6,000 | $32.35 | $194k | 68,284 | 30 h ago |
| Oct 8, 2026 | RIKER LAUREN Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -6,000 | $36.32 | $218k | 62,284 | 30 h ago |
| Oct 8, 2026 | RIKER LAUREN Senior Vice President, Finance | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 0 | 30 h ago |
| Dec 13, 2024 | GAUGLER DARYL Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -500 | $19.76 | $9,880 | 115,200 | Dec 16, 2024 |
| Nov 1, 2024 | Cross Shawn Chief Financial Officer | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 75,000 | Nov 5, 2024 |
| Nov 4, 2024 | Cross Shawn Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Cross ShawnChief Financial Officer
- GAUGLER DARYLChief Operating Officer
- RIKER LAURENSenior Vice President, Finance
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.